CNS Pharmaceuticals' common shares sponsored by 886 AG on the electronic trading platform Xetra

CNS PHARMACEUTICALS AG, (C35.F) a developer and marketer of patented natural nutraceutical products is pleased to announce that the Company’s common shares is sponsored by the German Securities Trading Bank 886 AG Wertpapier Handelsbank on the electronic trading platform Xetra. The electronic trading system Xetra is one the world’s most high-performance systems for the trading of around 300,000 international instruments. Xetra has a market share of over 90% percent in equity trading and is one of the fastest trading systems in the world with a round trip time at only two milliseconds. Financial institutions, securities trading houses and brokers can participate in Xetra trading. Xetra operates independently of the trader’s location, permitting international participation. In fact, more than 130 participants from European countries outside Germany trade on Xetra.

“We are pleased to be sponsored on Xetra, that will enable our growing international investor base to trade our shares which are listed on the Deutsche Boerse much easier on one of the world’s best high-performance trading systems,” said Samuel Weisberger, President of CNS PHARMACEUTICALS AG.

CNS PHARMACEUTICALS AG

This is another step towards the company’s goal of establishing itself as the leading worldwide provider of clinically proven supplements that support / maintain cognitive and other memory-related brain functions.

The company firmly believes that if you are concerned about maintaining your mental sharpness, concentration and memory you should be taking MemorA-Z™ as the product represents the “next generation” of natural supplements available on our website www.memora-z.com. This fact is reinforced by a major study which utilized rigorous scientific standards such as an up-to-date prospective, double-blind process, a placebo controlled clinical trial with preset inclusion / exclusion criteria and outcome variables. This study found that the MemorA-Z™ formulation effected statistically significant stabilization in memory function.